These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 27726966

  • 1. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators.
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [Abstract] [Full Text] [Related]

  • 2. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A.
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [Abstract] [Full Text] [Related]

  • 3. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, Niegisch G, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, Choueiri TK, Pond GR.
    J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
    [Abstract] [Full Text] [Related]

  • 4. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S, Lee JL, Rozzi A, Kitamura H, Matsumoto K, Srinivas S, Morales-Barrera R, Carles J, Al-Wardat R, Al-Rabi K, Maakoseh M.
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [Abstract] [Full Text] [Related]

  • 5. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
    Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E, IMvigor130 Study Group.
    Lancet; 2020 May 16; 395(10236):1547-1557. PubMed ID: 32416780
    [Abstract] [Full Text] [Related]

  • 6. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

  • 7. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J.
    Eur Urol; 2016 Apr 15; 69(4):634-641. PubMed ID: 26264159
    [Abstract] [Full Text] [Related]

  • 8. Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
    Minato A, Ohno D, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N.
    In Vivo; 2024 Apr 15; 38(4):1927-1934. PubMed ID: 38936900
    [Abstract] [Full Text] [Related]

  • 9. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
    Sonpavde GP, Mariani L, Lo Vullo S, Raggi D, Giannatempo P, Bamias A, Crabb SJ, Bellmunt J, Yu EY, Niegisch G, Vaishampayan UN, Theodore C, Berthold DR, Srinivas S, Sridhar SS, Plimack ER, Rosenberg JE, Powles T, Galsky MD, Necchi A.
    J Urol; 2018 Dec 15; 200(6):1207-1214. PubMed ID: 30012366
    [Abstract] [Full Text] [Related]

  • 10. Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma.
    Huang SY, Wu CC, Hsieh MC, Rau KM, Chiang PH, Sung MT, Luo HL, Huang CC, Huang CH, Liu JM, Su HY.
    Oncology; 2020 Dec 15; 98(3):146-153. PubMed ID: 31794969
    [Abstract] [Full Text] [Related]

  • 11. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
    Hsieh MC, Su YL, Chiang PH, Rau KM, Chen YY, Huang CH.
    Int J Urol; 2016 May 15; 23(5):385-9. PubMed ID: 26992082
    [Abstract] [Full Text] [Related]

  • 12. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
    Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.
    Urol Oncol; 2018 Apr 15; 36(4):156.e9-156.e16. PubMed ID: 29051030
    [Abstract] [Full Text] [Related]

  • 13. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
    Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L.
    J Urol; 2018 May 15; 199(5):1149-1157. PubMed ID: 29158104
    [Abstract] [Full Text] [Related]

  • 14. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    Sonpavde G, Watson D, Tourtellott M, Cowey CL, Hellerstedt B, Hutson TE, Zhan F, Vogelzang NJ.
    Clin Genitourin Cancer; 2012 Mar 15; 10(1):1-5. PubMed ID: 22340630
    [Abstract] [Full Text] [Related]

  • 15. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A, Lo Vullo S, Raggi D, Gloghini A, Giannatempo P, Colecchia M, Mariani L.
    Eur Urol Focus; 2019 Sep 15; 5(5):853-856. PubMed ID: 29525380
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.
    Eur Urol; 2019 Oct 15; 76(4):524-532. PubMed ID: 31362898
    [Abstract] [Full Text] [Related]

  • 17. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
    Sonpavde G, Pond GR, Di Lorenzo G, Buonerba C, Rozzi A, Lanzetta G, Necchi A, Giannatempo P, Raggi D, Matsumoto K, Choueiri TK, Mullane S, Niegisch G, Albers P, Lee JL, Kitamura H, Kume H, Bellmunt J.
    Clin Genitourin Cancer; 2016 Dec 15; 14(6):494-498. PubMed ID: 27262369
    [Abstract] [Full Text] [Related]

  • 18. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
    Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C.
    BMC Cancer; 2017 Jul 19; 17(1):493. PubMed ID: 28724419
    [Abstract] [Full Text] [Related]

  • 19. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
    Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G.
    BJU Int; 2014 May 19; 113(5b):E137-43. PubMed ID: 24219029
    [Abstract] [Full Text] [Related]

  • 20. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 19; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.